{
  "docId": "019de077-60e9-755b-a2a9-f474a1c234cc",
  "docSlug": "c7a8fd91214a0cf2ae7cadcb747376a3",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 42,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a structured list format to map specific clinical challenges to corresponding methodological solutions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-60e9-755b-a2a9-f474a1c234cc/12",
  "deckHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc",
  "deckJsonHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc.json",
  "deckAnchorHref": "/decks/019de077-60e9-755b-a2a9-f474a1c234cc#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.23,
        "y": 0.75
      },
      "kind": "list",
      "text": "Collection of all AEs, including \"positive\" and MOA-related; Frequent assessment to define time course for resolution of drug effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ed4048f-f5ba-4bb0-8a37-4c57ae8375bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.23,
        "y": 0.18
      },
      "kind": "list",
      "text": "Blinded centralized raters for primary outcome measure; Dose-response in Phase 2 across 'functionally active' doses; Complementary studies with multiple 'functionally masking' arms; Pre- and post-dose expectancy questionnaire; Post-dose blinding questionnaire",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce3cd12d-0718-44c2-a704-2200fc2e9430",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.23,
        "y": 0.56
      },
      "kind": "list",
      "text": "Collection of ECGs in Phase 3 Clinical Trials; Dedicated TQT study in parallel with Phase 3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db3e4a06-47d6-4ba7-bcef-b03c6551e9cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.16,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "AE: adverse event; ECG: electrocardiogram; MOA: mechanism of action; TQT: thorough QT",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0fa1fb6-6c2d-4035-bdc0-97180c37a8fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.82,
        "x": 0.037,
        "y": 0.045
      },
      "kind": "title",
      "text": "Strategies to Address Key Drug Class Methodological Considerations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85d68e18-d262-48b5-b390-d4644fe6694b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "e1660b2a-0f0d-4552-b33a-5cc3d05bb670",
      "evidence": "list/bullet: Blinded centralized raters for primary outcome measure; Dose-response in Phase 2 across 'functionally active' doses; Complementary studies with multiple 'functionally masking' arms; Pre- and post-dose expect",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "a218c047-f9dd-43b1-b607-76eb8fa90d3b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-14 discuss MM120 ODT Lysergide D-tartrate program",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7f8a31e9-b9f6-4f56-a068-29db96bdffb0",
      "evidence": "Slides 9-12 discuss the potential to address large unmet needs",
      "position": 0,
      "objective": "Highlight the cost of inaction in addressing brain health disorders",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}